Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis.

Abstract

After combining etanercept with the prevailing treatment, the total costs of refractory JIA calculated per year were only slightly higher than those of traditional therapy. This finding must be evaluated in light of the reduced inflammatory activity of the joint disease and the probable reduction of lifetime pain and disability produced by the disease.